Quick Answer
Iterum Therapeutics plc reported Total Revenue of $0.00 for fiscal year 2021.
Iterum Therapeutics plc — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | $0.00 | $0.00 -100.0% |
$37.0K -95.7% |
| Revenue (ASC 606) | — | — | — | $0.00 | $0.00 -100.0% |
$37.0K -95.7% |
| Net Income | -$24.77M +35.4% |
-$38.37M +13.6% |
-$44.43M +51.5% |
-$91.56M -76.1% |
-$52.01M +49.6% |
-$103.13M -33.8% |
| Diluted EPS | -$1.26 +57.4% |
-$2.96 +18.5% |
-$3.63 +56.8% |
-$8.41 +74.1% |
-$32.49 | — |
| Total Assets | $44.59M +69.8% |
$26.26M -60.7% |
$66.83M -27.0% |
$91.51M +179.1% |
$32.79M +27.3% |
$25.75M -73.7% |
| Cash and Equivalents | $24.12M +297.4% |
$6.07M -71.2% |
$21.09M -23.2% |
$27.45M +89.2% |
$14.51M +202.2% |
$4.80M -89.2% |
| Long-Term Debt | — | $11.45M +13.5% |
$10.09M +45.7% |
$6.93M -69.1% |
$22.46M +194.6% |
$7.62M -41.7% |
| Stockholders Equity | -$4.08M +36.3% |
-$6.40M -122.9% |
$28.00M -44.3% |
$50.23M +199.4% |
-$50.56M -92.7% |
-$26.24M -136.6% |
| R&D Expense | $10.46M -73.8% |
$39.99M +127.0% |
$17.62M +64.5% |
$10.71M -49.2% |
$21.07M -76.8% |
$90.77M +32.2% |
| Operating Income | -$18.70M +60.6% |
-$47.47M -56.2% |
-$30.38M -23.8% |
-$24.54M +23.6% |
-$32.13M +68.5% |
-$102.02M -33.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $390.0K | — | +954.1% |
| Revenue (ASC 606) | September 30, 2025 | $390.0K | — | +954.1% |
| Net Income | September 30, 2025 | -$8.98M | -47.3% | -37.9% |
| Diluted EPS | September 30, 2025 | -$0.20 | +33.3% | -25.0% |
| Total Assets | September 30, 2025 | $32.50M | +104.1% | -4.4% |
| Cash and Equivalents | September 30, 2025 | $11.00M | -17.9% | -15.5% |
| Long-Term Debt | September 30, 2023 | $12.46M | +34.0% | +6.8% |
| Stockholders Equity | September 30, 2025 | -$7.38M | +35.9% | -89.9% |
| R&D Expense | September 30, 2025 | $1.26M | -59.4% | +26.1% |
| Operating Income | September 30, 2025 | -$7.73M | -58.2% | -39.8% |
- Iterum Therapeutics plc reported Total Revenue of $0.00 for fiscal year 2021.
- Iterum Therapeutics plc reported Revenue (ASC 606) of $0.00 for fiscal year 2021.
- Iterum Therapeutics plc reported Net Income of -$24.77 million for fiscal year 2024.
- Iterum Therapeutics plc showed an increase of +35.4% in Net Income compared to the prior fiscal year.
- Iterum Therapeutics plc reported Diluted EPS of $1.26 per share (loss) for fiscal year 2024.
- Iterum Therapeutics plc showed an increase of +57.4% in Diluted EPS compared to the prior fiscal year.
- Iterum Therapeutics plc reported Total Assets of $44.59 million for fiscal year 2024.
- Iterum Therapeutics plc showed an increase of +69.8% in Total Assets compared to the prior fiscal year.
- Iterum Therapeutics plc reported Cash and Equivalents of $24.12 million for fiscal year 2024.
- Iterum Therapeutics plc showed an increase of +297.4% in Cash and Equivalents compared to the prior fiscal year.
- Iterum Therapeutics plc reported Long-Term Debt of $11.45 million for fiscal year 2023.
- Iterum Therapeutics plc showed an increase of +13.5% in Long-Term Debt compared to the prior fiscal year.
- Iterum Therapeutics plc reported Stockholders Equity of -$4.08 million for fiscal year 2024.
- Iterum Therapeutics plc showed an increase of +36.3% in Stockholders Equity compared to the prior fiscal year.
- Iterum Therapeutics plc reported R&D Expense of $10.46 million for fiscal year 2024.
- Iterum Therapeutics plc showed a decrease of -73.8% in R&D Expense compared to the prior fiscal year.
- Iterum Therapeutics plc reported Operating Income of -$18.70 million for fiscal year 2024.
- Iterum Therapeutics plc showed an increase of +60.6% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: